CompletedNot Applicable

Does Fidaxomicin Therapy Reduce Spread of Clostridium Difficile?

United Kingdom203 participantsStarted 2015-01

Plain-language summary

This study evaluates whether patients with Clostridium difficile infection (CDI) who are treated with fidaxomicin have less contamination of their skin and surrounding environment with spores of C. difficile than patients treated with other drugs (metronidazole or vancomycin)

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of CDI (see above) * Prescribed fidaxomicin, vancomycin or metronidazole by attending physician Exclusion Criteria: * Patients whose clinical care team indicates it would be inappropriate to include him/her in the study (e.g. due to terminal illness) * In a patient receiving metronidazole or vancomycin, receipt of fidaxomicin within the previous 3 months * patients unable to give informed consent for whom no consultee is available to give approval * non-English speakers

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The presence of environmental contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.

Timeframe: Up to 28 days after treatment

The presence of skin contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.

Timeframe: Up to 28 days after treatment

Trial details

NCT IDNCT02461901

SponsorProfessor Mark Wilcox

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-12-31

View on ClinicalTrials.gov More Clostridium Difficile Infection trials

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

The presence of environmental contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.

Timeframe: Up to 28 days after treatment

The presence of skin contamination with C. difficile spores during and following treatment with fidaxomicin, vancomycin or metronidazole.

Timeframe: Up to 28 days after treatment